Preview

Нефрология

Расширенный поиск

ПРОРЕНИН И РЕНИН – НОВЫЕ МИШЕНИ ДЛЯ РЕНО- И КАРДИОПРОТЕКТИВНОЙ ТЕРАПИИ

https://doi.org/10.24884/1561-6274-2009-13-1-15-20

Полный текст:

Аннотация

Имеющиеся на сегодняшний день экспериментальные данные дают основание предполагать, что в условиях блокады ангиотензипревращающего фермента (АПФ) и АТ₁ - рецепторов к ангиотензину II (А-II), проренин и ренин могут проявлять свою профибротическую активность, действуя через специфический проренин/рениновый (П/Р) рецептор. Профибротический эффект проренин/ренина, хотя и обнаружен в основном в почечной ткани, не может считаться изолированным патофизиологическим феноменом и П/Р могут связываться со специфическим рецептором на поверхности кардиомиоцита. В настоящее время проходит клинические испытания новый препарат, единственный представитель группы прямых ингибиторов ренина-алискирен (aliskirеn), недавно одобренный комитетом FDA США в качестве препарата для лечения артериальной гипертензии. Однако до настоящего времени остается неясным вопрос, насколько клинически значимой окажется блокада (про) рениновых рецепторов в отношении развития почечного и сердечного фиброза. Предварительные данные клинических исследований алискирена обнадеживают: уровень микроальбуминурии в ходе его применения снижается на 61% по сравнению с 50% на фоне применения рамиприла. В настоящее время продолжаются два клинических исследования III фазы по оценке эффективности лечения алискиреном больных с хронической болезнью почек (ХБП): AVOID (Aliskiren in the Evaluation of Proteinuria in Diabetes) и AZTITUDE (Aliskiren Trial in Type 2 Diabetic Nephropathy). Результаты этих исследований должны дать новую информацию о влиянии терапии алискиреном на частоту и тяжесть осложнений диабета. Таким образом, открытие новых механизмов функционирования и значения ренин-ангиотензин-альдостероновой системы, по-видимому, в скором будущем создаст новые предпосылки к совершенствованию рено- и кардиопротективной терапии.

Об авторах

А. В. Смирнов
Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Россия

Научно-исследовательский институт нефрологии

197022 Санкт-Петербург, ул. Л. Толстого 17, НИИ Нефрологии СПбГМУ им. акад. И.П. Павлова; тел.: (812)-234-01-65



К. А. Смирнов
Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Россия

Научно-исследовательский институт нефрологии

197022 Санкт-Петербург, ул. Л. Толстого 17



Список литературы

1. Ruster C, Wolf G. Renin- angiotensin- aldosteron system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991

2. Danser AHJ. Local renin- angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759-768

3. van Kats JP, Schalekamp MADH, Verdouw PD et al. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60: 2311-2317

4. Border WA, Noble NA. Interaction of transforming growth factor- beta and angiotensin II in renal fibrosis. Hypertension 1998: 31: 181-188

5. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-І and renal fibrosis. Contib Nephrol 2001; 135: 153-160

6. Tokuda K, Kai H, Kuwahara F et al. Pressure- independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503

7. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272

8. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control proteinuria and angiotensin-converting enzyme inhibition: a patient- level meta-analysis. Ann Intern Med 2003; 139: 244-252

9. Devereux RB, Dahlof B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Cireulation 2004; 110: 1456-1462

10. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-1580

11. Border WA, Noble NA. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001; 21: 563-572

12. Kurtz A, Wagner C. Regulation of renin secretion by angiotensin II-AT 1 receptors. J Am Soc Nephrol 1999; 10 (Suppl. 11): S162-S168

13. Azizi M, Bissery A, Lamarie-Cliche M, Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004; 43: 785-790

14. Danser AHJ, Derkx FHM, Schalekamp MADH et al. Determination of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998; 16: 853-862

15. Luetscher JA, Kraemer FB, Wilson DM et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417

16. Deinum J, Ronn B, Mathiesen E et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42: 1006-1010

17. Maru I, Ohta J, Murata K et al. Molecular cloning and identification of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a renin-binding protein. J Biol Chem 1996; 271: 16294-16299

18. van Kesteren CAM, Danser AHJ, Derkx FHM et al. Mannose 6-phosphate receptor- mediated internalization and activation of prorenin by cardiac cells. Hypertension 1997; 30: 1389-1396

19. Saris JJ, van den Eijnden MMED, Lamers JMJ et al. Prorenin- induced myocyte proliferation: no role for intracellular angiotensin II. Hypertension 2002; 39: 573-577

20. Nguyen G, Delarue F, Berron J et al. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator ingibitor-1 antigen. Kidney Int 1996; 50: 1897-1903

21. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427

22. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-І 1 and matrix proteins through receptor- mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113

23. Saris JJ, Hoen PAC, Garrelds IM et al. Prorenin induces intracellular signaling in cardiomyocytes indepently of angiotensin II. Hypertension 2006; 48: 564-571

24. Burridge K, Wennerberg K. Rho and Rac take center stage Cell 2004; 116: 167-179

25. Huang Y, Noble NA, Zhang J et al. Renin-stimulated TGF-І 1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72: 45-52

26. Danser AHJ, Batenburg WW, van Esch JHM. Prorenin and the (pro)renin receptor-an update. Nephrol Dial Transplant 2007; 22: 1288-1292

27. Ichihara A, Hayashi M, Kaneshiro J et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135

28. Price DA, Porter ZE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-239

29. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blochers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812

30. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation 2004; 109: 2492-2499

31. Mc Murray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771

32. Ruilope LM, Aldigier JC, Ponticelli C et al. Safety of the combination of valsartan and benasepril in patients with chronic renal disease: European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18: 89-95

33. Krebs C, Hamming I, Sadaghiani S et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007; 72: 725-730

34. Steinmetz OM, Sadaghiani S, Panzer U et al. Antihypertensive therapy induces compartment-specific chemokine expression and a Th 1 immune response in the clipped kidney of Goldblat hypertensive rats. Am J Physiol Renal Physiol 2007; 292: F876-F887

35. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209: 129-139

36. Dancer JAH, van Kats JP, Admiraal PJJ et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37-48

37. Segall L, Covic A, Goldsmith DJH. Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol Dial Transplant 2007; 22: 2435-2439

38. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553

39. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-1456

40. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002; 39: e1-e8

41. O’Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49 276-284

42. Mitchell J, Oh B, Herron J et al. Once-daily aliskiren provides effective, smoth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006; 8 [5 Suppl. A]: A93 (P-209)

43. Feldman DL, Persohn E, Schutz H et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens 2006; 8 [ Suppl. A]: A80

44. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018

45. Uresin Y, Taylor A, Kilo C et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006; 24 [Suppl. 4]: S82

46. Villamil A, Chrysant S, Calhoun D et al. The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006; 8 [Suppl. A]: A101

47. Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11-20

48. Bomback AS, Klemmer PhJ. The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology 2007; 3: 486-491

49. Vecchio LD, Procacio M, Vigano S, Cusi D. Mechanism of Disease: the role of aldosterone in Kidney damage and clinical benefits of its blockade.Nature Clinical Practice Nephrology 2007; 3 : 42-49

50. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci2006; 100: 9-16

51. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123

52. Shafig MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008; 121: 265-271


Для цитирования:


Смирнов А.В., Смирнов К.А. ПРОРЕНИН И РЕНИН – НОВЫЕ МИШЕНИ ДЛЯ РЕНО- И КАРДИОПРОТЕКТИВНОЙ ТЕРАПИИ. Нефрология. 2009;13(1):15-20. https://doi.org/10.24884/1561-6274-2009-13-1-15-20

For citation:


Smirnov A.V., Smirnov K.A. PRORENIN AND RENIN – NEW TARGETS FOR RENO- AND CARDIOPROTECTIVE THERAPY. Nephrology (Saint-Petersburg). 2009;13(1):15-20. (In Russ.) https://doi.org/10.24884/1561-6274-2009-13-1-15-20

Просмотров: 124


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)